NBIX Neurocrine Biosciences Inc

Price (delayed)

$96.08

Market cap

$9.18B

P/E Ratio

126.42

Dividend/share

N/A

EPS

$0.76

Enterprise value

$9.39B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
Neurocrine Biosciences's revenue has increased by 16% YoY and by 7% QoQ
The company's equity rose by 15% YoY
The price to earnings (P/E) is 94% higher than the last 4 quarters average of 64.5
NBIX's EPS has dropped by 82% year-on-year and by 20% since the previous quarter

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
95.58M
Market cap
$9.18B
Enterprise value
$9.39B
Valuations
Price to earnings (P/E)
126.42
Price to book (P/B)
6.58
Price to sales (P/S)
7.58
EV/EBIT
79.87
EV/EBITDA
72.65
EV/Sales
7.78
Earnings
Revenue
$1.21B
EBIT
$117.6M
EBITDA
$129.3M
Free cash flow
$102.2M
Per share
EPS
$0.76
Free cash flow per share
$1.07
Book value per share
$14.61
Revenue per share
$12.67
TBVPS
$22.5
Balance sheet
Total assets
$2.14B
Total liabilities
$753.4M
Debt
$480.2M
Equity
$1.39B
Working capital
$764.7M
Liquidity
Debt to equity
0.35
Current ratio
4.02
Quick ratio
3.66
Net debt/EBITDA
1.62
Margins
EBITDA margin
10.7%
Gross margin
98.7%
Net margin
5.9%
Operating margin
6.1%
Efficiency
Return on assets
3.5%
Return on equity
5.3%
Return on invested capital
6.1%
Return on capital employed
6.2%
Return on sales
9.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
0.92%
1 week
-1.44%
1 month
0.64%
1 year
-2.15%
YTD
12.81%
QTD
-1.44%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.21B
Gross profit
$1.19B
Operating income
$74.1M
Net income
$71.4M
Gross margin
98.7%
Net margin
5.9%
The net margin has shrunk by 85% YoY and by 25% QoQ
The company's net income has shrunk by 82% YoY and by 20% QoQ
The operating margin has plunged by 53% YoY and by 32% from the previous quarter
The operating income has declined by 45% year-on-year and by 28% since the previous quarter

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
P/E
126.42
P/B
6.58
P/S
7.58
EV/EBIT
79.87
EV/EBITDA
72.65
EV/Sales
7.78
The price to earnings (P/E) is 94% higher than the last 4 quarters average of 64.5
NBIX's EPS has dropped by 82% year-on-year and by 20% since the previous quarter
NBIX's price to book (P/B) is 52% lower than its 5-year quarterly average of 13.7
The company's equity rose by 15% YoY
The stock's price to sales (P/S) is 60% less than its 5-year quarterly average of 18.7 and 6% less than its last 4 quarters average of 8.0
Neurocrine Biosciences's revenue has increased by 16% YoY and by 7% QoQ

Efficiency

How efficient is Neurocrine Biosciences business performance
The ROE has plunged by 87% YoY and by 23% from the previous quarter
Neurocrine Biosciences's return on assets has shrunk by 86% YoY and by 22% QoQ
The company's return on invested capital fell by 34% YoY and by 12% QoQ
NBIX's return on sales is down by 20% year-on-year and by 13% since the previous quarter

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
NBIX's total assets is 185% more than its total liabilities
Neurocrine Biosciences's quick ratio has decreased by 32% YoY
The company's current ratio fell by 30% YoY
The debt is 65% lower than the equity
The company's equity rose by 15% YoY
The debt is up by 12% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.